Digital support to reduce salt intake for people with type 2 diabetes and kidney disease
Official title: SBI 2024-2026 STENO FOOD CONCEPT
Run by Steno Diabetes Center Copenhagen · NCT07485075 · Data updated 2026-11-12
This project will test whether a smartphone app can help people with type 2 diabetes and moderately reduced kidney function eat less salt and follow kidney-friendly protein guidance over six months.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 74 Years |
| Sex | All |
| Enrollment | 104 (estimated) |
| Sponsor | Steno Diabetes Center Copenhagen Academic / other |
| Locations | 2 sites (Herlev, Captial Region of Denmark and 1 other locations) |
| Status | Recruiting |
| Started | March 20, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT07485075 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–74 with type 2 diabetes, moderately reduced kidney function (eGFR 30–59 ml/min) and albuminuria (UACR >30 mg/g), BMI <35, stable medication for ≥3 months, and who can read Danish are ideal candidates.
✕Probably not a fit
Patients with type 1 or other non–type 2 diabetes, eGFR outside 30–59 ml/min, current vegan diet, active cancer, short bowel syndrome or celiac disease, use of sodium tablets, or those unable to use the digital platform or read Danish are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This controlled clinical trial compares a personalized digital education program (the StenoFOOD app) to standard outpatient care for people with type 2 diabetes and moderately reduced kidney function. Participants are recruited from Steno Diabetes Center Copenhagen (intervention) and Nordsjællands Hospital (control) and are followed for six months. The primary outcome is change in sodium intake estimated from 24-hour urinary sodium; secondary outcomes track protein intake and exploratory outcomes include blood pressure, albuminuria, electrolyte excretion, food literacy, digital health literacy, and patient-reported measures. Eligibility focuses on adults with eGFR 30–59 ml/min and albuminuria, stable medical treatment, BMI <35, and the ability to read Danish.
Why it matters
Potential benefit: If successful, the app could help patients reduce salt intake, improve blood pressure control, and support kidney-protective dietary habits.
How similar studies have gone: Previous digital dietary interventions have produced modest diet and blood pressure improvements in other populations, but using an app to deliver KDIGO-specific sodium and protein guidance in people with type 2 diabetes and CKD is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 2 diabetes (ICD-10 DE11.x) * Age 18-74 years * BMI \< 35 kg/m² * eGFR 30-59 ml/min and UACR \> 30 mg/g * Stable medication for ≥3 months * Ability to read and understand Danish Exclusion Criteria: * Type 1 diabetes or other diabetes types * Current vegan diet * Active cancer * Short bowel syndrome or celiac disease * Use of sodium chloride tablets * No access to digital platform (intervention group only)
Where it's running
-
Steno Diabetes Center Copenhagen,
Herlev, Captial Region of Denmark, Denmark Recruiting -
Nordsjællands Hospital, Hillerød
Hillerød, Captial Region of Denmark, Denmark Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
See if short-term supervised resistance training improves muscle health and function in frail older adults with type 2 diabetes
This study tests whether a brief, supervised resistance training program can improve skeletal muscle health and physical function in frail adults over 65 who have type 2 diabetes.
-
Empagliflozin, Metformin, or both for muscle energy in adults with type 2 diabetes
This study tests whether empagliflozin, metformin, or their combination can improve skeletal muscle oxidative capacity and microvascular reactivity in adults recently diagnosed with type 2 diabetes.
-
Perioperative Meditation Music for Type 2 Diabetes Patients Undergoing Elective Surgery
We’re testing whether playing self-selected meditation music around surgery helps adults with type 2 diabetes stay calm, sleep better, and keep blood sugar steadier.
-
How metformin works in people with or without the SLC16A11 risk variant
This study tests whether the SLC16A11 genetic variant changes how adults with type 2 diabetes respond to metformin over 6 months.
-
Pedal Pump Device for Lower Extremity Edema in Hospitalized Patients
This study tests a foot-pump device to see if it is tolerable and can help reduce swelling in the legs of hospitalized patients with edema.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.